Drafting services

Autodesk's AECO line alone runs at $3.583B and grew 22%, Trimble's AECO segment adds $1.499B and Bentley carries $1.46B of ARR in infrastructure engineering, and the file formats are the lock — RVT and DGN are read properly only by their owners. An entrant does not compete on features but on interoperability it does not control. Note the sizing here is a floor of $5.1B from Autodesk's and Trimble's disclosed AECO revenue alone, not a market estimate.

A $12.35B software market in 2026 growing 15.5% a year, and the two ends of it are both closed. Esri holds an estimated 35-40% of it with ArcGIS and does not disclose a revenue figure, so the leader cannot even be sized from filings; beneath it QGIS is a mature, free, OGC-compliant desktop and the open-source stack (PostGIS, GeoServer, Leaflet, MapLibre) sets the price of the core capability at zero. An entrant is squeezed exactly as in enterprise search: free below, an unpriceable incumbent above. Distribution is the harder cut. The paying buyer is a municipality, utility or provincial agency that buys on a multi-year Enterprise Agreement through procurement, and Esri Canada sells that agreement plus its own consulting practice into the same account — the channel and the incumbent are the same organisation. Note what this record is not: 541370 is surveying and mapping SERVICES, and the fragmented implementation layer sitting on top of ArcGIS is a different market with different economics. That layer is a services business, not a software business, and is not screened here.

Two private LIMS houses that have each sold into labs for about forty years hold the top of this market, and validation keeps their customers in place. LabWare (Wilmington, Delaware; founded 1987 and still run by its founder) claims 30,000 laboratories at 2,500 companies in 125 countries, with all R&D in Wilmington [C]. StarLIMS (Hollywood, Florida; founded 1986) belonged to Abbott from 2010 to 2021. Francisco Partners bought it from Abbott in July 2021, terms not disclosed [B, FP release]. On 13 January 2026 Turn/River Capital bought it outright and Francisco Partners exited [B, release], so it has had three owners in five years. StarLIMS claims 1,100+ customers in 2,000+ labs [C]. LabVantage (Somerset, NJ) is the third independent. It is private, has never disclosed an owner, and grew by buying Life Technologies' SQL*LIMS in 2009 [B]. The instrument makers sell LIMS too, and they bundle it with their hardware: Thermo Fisher (SampleManager for QC and manufacturing, Watson for bioanalysis, Core LIMS for R&D), Agilent (SLIMS, from its 2018 Genohm deal), Waters (NuGenesis) and Illumina (Clarity LIMS, for genomics labs; it is not a Revvity product). None of them reports a LIMS revenue line. The R&D notebook side is where the money went: Benchling raised $100M at a $6.1B valuation in 2021 [B, release], and Siemens bought Dotmatics for $5.1B in July 2025, a company expected to earn more than $300M in FY2025 [B, Siemens release]. Siemens does have a lab play, then, but it came through Dotmatics, not Opcenter. At the bottom, CloudLIMS publishes per-user prices: $285 a user a month at 5 users, falling to $42 at 100 users, billed annually [C, pricing page]. LabLynx, CloudLIMS and Kitchener's Scispot (about $10M raised) already serve small labs. The lock-in is the validation, not the software. A pharma QC or GLP lab that switches LIMS has to revalidate the new system under 21 CFR Part 11 or GxP, and an ISO 17025 lab has to show its accreditation body that results stay traceable through the move. Instrument interfaces, specifications and years of audit trail have to be migrated too. Customers stay for decades, which is why both leaders can be thirty-plus years old. How it differs from its neighbours. The clinical-trial and R&D data record covers EDC, CTMS and the R&D cloud, where Benchling and Dotmatics live. This record is the system of record for the sample and the result in testing and QC labs. The food-safety record covers plant-floor safety and FSMA 204 traceability, not the lab that tests the samples. Imaging/PACS is radiology. Clinical lab systems are a separate, hospital-bought market. Epic's Beaker module, Clinisys (Roper Technologies) and Orchard Software, which Clinisys bought from Francisco Partners in July 2025 [B], are listed here only to mark that boundary. Incumbent vulnerability decides it: the two leaders are stable, the instrument makers bundle LIMS with their hardware, and the low end already has vendors that publish their prices.